$2.24
2.28%
Nasdaq, Apr 21, 08:45 pm CET
ISIN
US01438T1060
Symbol
ALDX
Sector
Industry

Aldeyra Therapeutics, Inc. Stock price

$2.19
-4.12 65.29% 1M
-3.36 60.54% 6M
-2.80 56.11% YTD
-1.78 44.84% 1Y
-1.75 44.42% 3Y
-0.72 24.74% 5Y
-8.78 80.04% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
+0.18 8.96%
ISIN
US01438T1060
Symbol
ALDX
Sector
Industry

Key metrics

Market capitalization $130.76m
Enterprise Value $44.91m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.84
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-60.12m
Free Cash Flow (TTM) Free Cash Flow $-43.21m
Cash position $101.15m
EPS (TTM) EPS $-0.94
P/E forward negative
P/S forward 4.32
EV/Sales forward 1.48
Short interest 7.15%
Show more

Is Aldeyra Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Aldeyra Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Aldeyra Therapeutics, Inc. forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Aldeyra Therapeutics, Inc. forecast:

Buy
100%

Financial data from Aldeyra Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.25 0.25
4% 4%
-
-0.25 -0.25
4% 4%
-
- Selling and Administrative Expenses 11 11
11% 11%
-
- Research and Development Expense 48 48
64% 64%
-
-60 -60
41% 41%
-
- Depreciation and Amortization 0.25 0.25
4% 4%
-
EBIT (Operating Income) EBIT -60 -60
40% 40%
-
Net Profit -56 -56
49% 49%
-

In millions USD.

Don't miss a Thing! We will send you all news about Aldeyra Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aldeyra Therapeutics, Inc. Stock News

Positive
Seeking Alpha
about 5 hours ago
Aldeyra Therapeutics' stock offers a compelling contrarian opportunity, rebounding 70% after a 75% drop due to an FDA CRL for Reproxalap in dry eye disease. The FDA requested additional efficacy data. Aldeyra already has two trials with data expected in Q2 2025, aiming for NDA resubmission by mid-2025. Reproxalap targets upstream inflammation, offering rapid symptom relief in a large market, wi...
Neutral
GlobeNewsWire
about 7 hours ago
SAN FRANCISCO, April 21, 2025 (GLOBE NEWSWIRE) -- On April 3, 2025 investors in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) saw the price of their shares crash over 70% after the company announced that it received a Complete Response Letter (“CRL”) from the FDA for the resubmission of the New Drug Application (“NDA”) of reproxalap, an investigational drug candidate, for the treatment of dry eye d...
Neutral
GlobeNewsWire
3 days ago
SAN FRANCISCO, April 18, 2025 (GLOBE NEWSWIRE) -- On April 3, 2025 investors in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) saw the price of their shares crash over 70% after the company announced that it received a Complete Response Letter (“CRL”) from the FDA for the resubmission of the New Drug Application (“NDA”) of reproxalap, an investigational drug candidate, for the treatment of dry eye d...
More Aldeyra Therapeutics, Inc. News

Company Profile

Aldeyra Therapeutics, Inc. operates as a biotechnology company. It primarily focuses on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are thought to be caused in part by naturally occurring toxic chemical species known as free aldehydes. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Head office United States
CEO Todd Brady
Employees 9
Founded 2004
Website www.aldeyra.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today